PubRank

Curtis C Harris

Author PubWeight™ 315.79‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006 40.09
2 Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006 23.59
3 The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002 12.39
4 MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008 12.26
5 Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010 7.39
6 Radical causes of cancer. Nat Rev Cancer 2003 5.45
7 KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012 4.38
8 Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007 4.19
9 Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet 2012 3.69
10 MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A 2009 3.64
11 Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol 2010 3.49
12 Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2009 3.40
13 The landscape of recombination in African Americans. Nature 2011 3.06
14 MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 2009 3.03
15 p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005 2.78
16 The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med 2008 2.72
17 Reprogramming of miRNA networks in cancer and leukemia. Genome Res 2010 2.65
18 Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst 2011 2.61
19 Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011 2.57
20 p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol 2009 2.46
21 Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 2008 2.45
22 p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res 2003 2.40
23 Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 2002 2.38
24 TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ 2004 2.23
25 TP53 and liver carcinogenesis. Hum Mutat 2003 2.23
26 p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res 2004 2.08
27 p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol 2008 2.04
28 Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A 2002 2.04
29 BLM heterozygosity and the risk of colorectal cancer. Science 2002 2.03
30 Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer 2011 2.02
31 Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 2003 1.97
32 Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One 2009 1.94
33 MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 2010 1.89
34 Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci U S A 2004 1.87
35 Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Res 2005 1.86
36 Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 2013 1.86
37 Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res 2008 1.83
38 A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet 2013 1.82
39 Functional interaction between BLM helicase and 53BP1 in a Chk1-mediated pathway during S-phase arrest. J Cell Biol 2004 1.82
40 The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J Clin Invest 2003 1.82
41 POT1 and TRF2 cooperate to maintain telomeric integrity. Mol Cell Biol 2005 1.74
42 BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination. EMBO J 2003 1.71
43 Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2005 1.70
44 Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-β signaling. PLoS Genet 2013 1.69
45 Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res 2009 1.67
46 Microenvironmental modulation of asymmetric cell division in human lung cancer cells. Proc Natl Acad Sci U S A 2010 1.66
47 Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. Cancer Res 2003 1.64
48 Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol 2010 1.64
49 The rectal cancer microRNAome--microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res 2012 1.61
50 Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 2005 1.61
51 Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst 2007 1.58
52 Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res 2002 1.53
53 p53: 25 years after its discovery. Trends Pharmacol Sci 2004 1.49
54 Telomere recombination requires the MUS81 endonuclease. Nat Cell Biol 2009 1.45
55 Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo. Cancer Res 2004 1.45
56 Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics 2008 1.44
57 Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res 2009 1.44
58 The role of microRNAs in colorectal cancer. Cancer J 2012 1.44
59 The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res 2005 1.42
60 A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene 2003 1.40
61 WNT16B is a new marker of cellular senescence that regulates p53 activity and the phosphoinositide 3-kinase/AKT pathway. Cancer Res 2009 1.39
62 Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 2002 1.35
63 p53 functions in the incorporation step in DNA base excision repair in mouse liver mitochondria. Oncogene 2004 1.33
64 p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. Cancer Res 2003 1.32
65 ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation. Mol Cell Biol 2005 1.31
66 Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls. Carcinogenesis 2003 1.31
67 The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res 2011 1.29
68 Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 2003 1.29
69 Novel splice variants of ING4 and their possible roles in the regulation of cell growth and motility. J Biol Chem 2006 1.28
70 Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology 2010 1.28
71 Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis Rheum 2013 1.28
72 Tumor suppressor miR-22 determines p53-dependent cellular fate through post-transcriptional regulation of p21. Cancer Res 2011 1.27
73 Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis 2004 1.25
74 ING1 represses transcription by direct DNA binding and through effects on p53. Cancer Res 2003 1.25
75 Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis. Int J Cancer 2006 1.23
76 Detection of HPV DNA in esophageal cancer specimens from different regions and ethnic groups: a descriptive study. BMC Cancer 2010 1.22
77 The processing of Holliday junctions by BLM and WRN helicases is regulated by p53. J Biol Chem 2002 1.22
78 Superoxide fluxes limit nitric oxide-induced signaling. J Biol Chem 2006 1.22
79 p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest 2013 1.21
80 Identification of carboxypeptidase E and gamma-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. Hum Pathol 2004 1.20
81 Nitric oxide is a key component in inflammation-accelerated tumorigenesis. Cancer Res 2008 1.19
82 Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. Cancer Res 2007 1.19
83 Alterations of microRNAs contribute to colon carcinogenesis. Semin Oncol 2011 1.19
84 Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res 2012 1.18
85 Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res 2004 1.15
86 Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. Nat Cell Biol 2010 1.14
87 Chronic epithelial NF-κB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation. Proc Natl Acad Sci U S A 2012 1.13
88 The role of p53 in base excision repair following genotoxic stress. Carcinogenesis 2003 1.13
89 Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J Exp Med 2010 1.12
90 Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease. Environ Mol Mutagen 2004 1.12
91 The p53 network in lung carcinogenesis. Oncogene 2002 1.11
92 Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 2009 1.10
93 MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006 1.10
94 Tumor suppressor p53 represses transcription of RECQ4 helicase. Oncogene 2005 1.10
95 Reviewing the current classification of inhibitor of growth family proteins. Cancer Sci 2009 1.09
96 The reemergence of nitric oxide and cancer. Nitric Oxide 2008 1.09
97 Cellular stress induced alterations in microRNA let-7a and let-7b expression are dependent on p53. PLoS One 2011 1.08
98 The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase. Oncogene 2004 1.08
99 BLM helicase facilitates Mus81 endonuclease activity in human cells. Cancer Res 2005 1.07
100 Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. Eur J Cancer 2012 1.07
101 Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women. Carcinogenesis 2010 1.07
102 p53 modulates RPA-dependent and RPA-independent WRN helicase activity. Cancer Res 2005 1.06
103 Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res 2004 1.06
104 Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol Biomarkers Prev 2007 1.05
105 WNT10B functional dualism: beta-catenin/Tcf-dependent growth promotion or independent suppression with deregulated expression in cancer. Mol Biol Cell 2007 1.05
106 Less efficient g2-m checkpoint is associated with an increased risk of lung cancer in African Americans. Cancer Res 2005 1.05
107 Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. J Natl Cancer Inst 2007 1.05
108 Functional diversity of human protection of telomeres 1 isoforms in telomere protection and cellular senescence. Cancer Res 2007 1.04
109 Chronic inflammation promotes retinoblastoma protein hyperphosphorylation and E2F1 activation. Cancer Res 2005 1.04
110 A small molecule inhibitor of the BLM helicase modulates chromosome stability in human cells. Chem Biol 2013 1.04
111 Childhood exposure to secondhand smoke and functional mannose binding lectin polymorphisms are associated with increased lung cancer risk. Cancer Epidemiol Biomarkers Prev 2009 1.04
112 Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res 2005 1.03
113 Polymorphism Interaction Analysis (PIA): a method for investigating complex gene-gene interactions. BMC Bioinformatics 2008 1.02
114 Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line. Int J Cancer 2010 1.00
115 Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma. Clin Cancer Res 2010 0.99
116 High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. Int J Cancer 2013 0.99
117 3'-UTR and functional secretor haplotypes in mannose-binding lectin 2 are associated with increased colon cancer risk in African Americans. Cancer Res 2012 0.99
118 rs4919510 in hsa-mir-608 is associated with outcome but not risk of colorectal cancer. PLoS One 2012 0.98
119 Plasma microRNAs: a potential biomarker for colorectal cancer? Gut 2009 0.98
120 microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma. Int J Cancer 2012 0.97
121 Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma. Cancer Res 2013 0.96
122 Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proc Natl Acad Sci U S A 2012 0.96
123 Admixture mapping of lung cancer in 1812 African-Americans. Carcinogenesis 2010 0.95
124 Expression and localization of Werner syndrome protein is modulated by SIRT1 and PML. Mech Ageing Dev 2007 0.95
125 A key role of microRNA-29b for the suppression of colon cancer cell migration by American ginseng. PLoS One 2013 0.95
126 NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression. Int J Cancer 2012 0.95
127 Genetic reduction of circulating insulin-like growth factor-1 inhibits azoxymethane-induced colon tumorigenesis in mice. Mol Carcinog 2009 0.94
128 Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis 2004 0.94
129 MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer. Int J Cancer 2012 0.93
130 Quantitative detection of p53 mutations in plasma DNA from tobacco smokers. Cancer Res 2006 0.93
131 p53 governs telomere regulation feedback too, via TRF2. Aging (Albany NY) 2011 0.93
132 MicroRNAs and inflammation in the pathogenesis and progression of colon cancer. Dig Dis 2012 0.92
133 UV-C-induced DNA damage leads to p53-dependent nuclear trafficking of PML. Oncogene 2003 0.92
134 The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest. PLoS One 2013 0.91
135 Reproductive and hormonal factors and the risk of nonsmall cell lung cancer. Int J Cancer 2011 0.91
136 An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers. J Thorac Oncol 2015 0.90
137 Elevated lung cancer risk is associated with deficiencies in cell cycle checkpoints: genotype and phenotype analyses from a case-control study. Int J Cancer 2010 0.90
138 KRAS-LCS6 genotype as a prognostic marker in early-stage CRC--letter. Clin Cancer Res 2012 0.89
139 Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance. PLoS One 2011 0.89
140 ING2 is upregulated in colon cancer and increases invasion by enhanced MMP13 expression. Int J Cancer 2009 0.88
141 Differential effects of reactive nitrogen species on DNA base excision repair initiated by the alkyladenine DNA glycosylase. Carcinogenesis 2009 0.87
142 A combined prognostic serum interleukin-8 and interleukin-6 classifier for stage 1 lung cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. J Thorac Oncol 2014 0.87
143 Telomerase activity in pleural malignant mesotheliomas. Lung Cancer 2011 0.86
144 Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer. Oncol Rep 2006 0.85
145 Macrophages, nitric oxide and microRNAs are associated with DNA damage response pathway and senescence in inflammatory bowel disease. PLoS One 2012 0.85
146 Targeted disruption of Ing2 results in defective spermatogenesis and development of soft-tissue sarcomas. PLoS One 2010 0.85
147 MicroRNA Involvement in Human Cancers. Clin Chem 2013 0.84
148 Germline variation in NCF4, an innate immunity gene, is associated with an increased risk of colorectal cancer. Int J Cancer 2013 0.84
149 Tumor suppressor p53 (TP53) at the crossroads of the exposome and the cancer genome. Proc Natl Acad Sci U S A 2012 0.84
150 Occupation, gender, race, and lung cancer. J Occup Environ Med 2008 0.83
151 Radon, secondhand smoke, glutathione-S-transferase M1 and lung cancer among women. Int J Cancer 2006 0.83
152 A novel ING2 isoform, ING2b, synergizes with ING2a to prevent cell cycle arrest and apoptosis. FEBS Lett 2008 0.83
153 Nitric oxide is a signaling molecule that regulates gene expression. Methods Enzymol 2005 0.82
154 EGFR somatic mutations in lung tumors: radon exposure and passive smoking in former- and never-smoking U.S. women. Cancer Epidemiol Biomarkers Prev 2012 0.82
155 Recent progress in carcinogenesis, progression and therapy of lung cancer: the 19th Hiroshima Cancer Seminar: the 3rd Three Universities' Consortium International Symposium, November 2009. Jpn J Clin Oncol 2010 0.81
156 Japan-US Cooperative Cancer Research Seminar on molecular epidemiological characteristics of lung and colon cancer development among atomic-bomb survivors, Bethesda, USA, February 23-24, 2006. Cancer Sci 2006 0.80
157 Human lung cancer cells and tissues partially recapitulate the homeobox gene expression profile of embryonic lung. Lung Cancer 2002 0.79
158 MicroRNAs as molecular classifiers for cancer. Cell Cycle 2011 0.78
159 TP53 mutation spectrum in lung cancer is not different in women and men. Cancer Epidemiol Biomarkers Prev 2005 0.78
160 Cause and Prevention of Human Cancer. Carcinogenesis 2015 0.76
161 The development of molecular epidemiology to elucidate cancer risk and prognosis: a historical perspective. Int J Mol Epidemiol Genet 2010 0.75
162 Innate immunity gene polymorphisms and the risk of colorectal neoplasia. Carcinogenesis 2013 0.75
163 A primate-specific microRNA enters the lung cancer landscape. Proc Natl Acad Sci U S A 2013 0.75
164 Manganese superoxide dismutase gene coding region polymorphisms lack clinical incidence in general population. DNA Cell Biol 2008 0.75
165 Sixteenth Aspen Cancer Conference: Mechanisms of Carcinogenesis, Cancer Prevention, and Cancer Therapy. Mol Carcinog 2002 0.75
166 The Nineteenth Aspen Cancer Conference: mechanisms of toxicity, carcinogenesis, cancer prevention, and cancer therapy, 2004. Mol Carcinog 2005 0.75
167 A functional analysis of G23A polymorphism and the alternative splicing in the expression of the XPA gene. Cell Mol Biol Lett 2010 0.75
168 The twenty-second Aspen Cancer Conference: Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention, and Cancer Therapy, 2007. Mol Carcinog 2008 0.75
169 The 23rd Aspen Cancer Conference: Mechanisms of toxicity, carcinogenesis, cancer prevention and cancer therapy 2008. Mol Carcinog 2009 0.75
170 The 24th Aspen Cancer Conference: Mechanisms of toxicity, carcinogenesis, cancer prevention and cancer therapy 2009. Mol Carcinog 2010 0.75
171 Seventeenth Aspen Cancer Conference: mechanisms of toxicity, carcinogenesis, cancer prevention, and cancer therapy. Mol Carcinog 2003 0.75
172 The Twenty-First Aspen Cancer Conference: Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention, and Cancer Therapy, 2006. Mol Carcinog 2007 0.75
173 The 20th Aspen Cancer Conference: Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention, and Cancer Therapy 2005. Mol Carcinog 2008 0.75